Unicycive Gross Profit from 2010 to 2024

UNCY Stock

USD 0.68 0 0.29%

Unicycive Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to about 595.8 K in 2024. Gross Profit is the profit Unicycive Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

675 K

Current Value

595.8 K

Quarterly Volatility

315 K

Credit Downgrade

Yuan Drop

Covid

Check Unicycive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unicycive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 77.9 K, Net Interest Income of 429.4 K or Depreciation And Amortization of 386.4 K, as well as many indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Unicycive financial statements analysis is a perfect complement when working with Unicycive Therapeutics Valuation or Volatility modules.

Check out the analysis of Unicycive Therapeutics Correlation against competitors.

For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

Latest Unicycive Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Unicycive Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Unicycive Therapeutics minus its cost of goods sold. It is profit before Unicycive Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Unicycive Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unicycive Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Unicycive Gross Profit Regression Statistics

	Arithmetic Mean	147,322
	Geometric Mean	3,734
	Coefficient Of Variation	213.84
	Mean Deviation	237,316
	Median	(1,000.00)
	Standard Deviation	315,039
	Sample Variance	99.2B
	Range	952K
	R-Value	0.66
	Mean Square Error	60.5B
	R-Squared	0.43
	Significance	0.01
	Slope	46,407
	Total Sum of Squares	1.4T

Unicycive Gross Profit History

	2024	595.8 K
	2023	675 K
	2022	951 K

Other Fundumenentals of Unicycive Therapeutics

Gross Profit Margin

Unicycive Therapeutics Gross Profit component correlations

	Net Tangible Assets	Retained Earnings	Accounts Payable	Total Current Assets	Common Stock	Total Assets	Total Stockholder Equity	Net Debt	Total Liab	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Property Plant Equipment	Current Deferred Revenue
Net Tangible Assets		-0.91	0.93	0.88	-0.3	0.83	0.25	-0.81	0.77	0.19	-0.51	0.82	0.23	-0.24	-0.68	0.68
Retained Earnings	-0.91		-0.81	-0.75	0.18	-0.66	0.15	0.62	-0.95	0.2	0.38	-0.9	0.17	0.1	0.85	-0.88
Accounts Payable	0.93	-0.81		0.78	-0.49	0.79	0.29	-0.71	0.63	0.24	-0.38	0.8	0.26	-0.15	-0.46	0.58
Total Current Assets	0.88	-0.75	0.78		-0.26	0.97	0.5	-0.98	0.71	0.45	-0.41	0.74	0.48	-0.17	-0.64	0.63
Common Stock	-0.3	0.18	-0.49	-0.26		-0.24	-0.28	0.21	-0.07	-0.33	-0.32	-0.04	-0.27	-0.45	0.05	0.11
Total Assets	0.83	-0.66	0.79	0.97	-0.24		0.59	-0.97	0.59	0.55	-0.4	0.76	0.57	-0.19	-0.45	0.59
Total Stockholder Equity	0.25	0.15	0.29	0.5	-0.28	0.59		-0.64	-0.26	0.99	-0.23	-0.04	1.0	-0.22	0.28	-0.29
Net Debt	-0.81	0.62	-0.71	-0.98	0.21	-0.97	-0.64		-0.56	-0.59	0.48	-0.65	-0.62	0.27	0.5	-0.52
Total Liab	0.77	-0.95	0.63	0.71	-0.07	0.59	-0.26	-0.56		-0.31	-0.28	0.85	-0.29	-0.01	-0.94	0.94
Net Invested Capital	0.19	0.2	0.24	0.45	-0.33	0.55	0.99	-0.59	-0.31		-0.11	-0.09	0.99	-0.1	0.33	-0.34
Short Long Term Debt	-0.51	0.38	-0.38	-0.41	-0.32	-0.4	-0.23	0.48	-0.28	-0.11		-0.35	-0.22	0.95	0.3	-0.3
Capital Stock	0.82	-0.9	0.8	0.74	-0.04	0.76	-0.04	-0.65	0.85	-0.09	-0.35		-0.06	-0.14	-0.64	0.93
Net Working Capital	0.23	0.17	0.26	0.48	-0.27	0.57	1.0	-0.62	-0.29	0.99	-0.22	-0.06		-0.21	0.3	-0.31
Short Term Debt	-0.24	0.1	-0.15	-0.17	-0.45	-0.19	-0.22	0.27	-0.01	-0.1	0.95	-0.14	-0.21		0.03	-0.1
Property Plant Equipment	-0.68	0.85	-0.46	-0.64	0.05	-0.45	0.28	0.5	-0.94	0.33	0.3	-0.64	0.3	0.03		-0.8
Current Deferred Revenue	0.68	-0.88	0.58	0.63	0.11	0.59	-0.29	-0.52	0.94	-0.34	-0.3	0.93	-0.31	-0.1	-0.8

Click cells to compare fundamentals

About Unicycive Therapeutics Financial Statements

Unicycive Therapeutics investors use historical fundamental indicators, such as Unicycive Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unicycive Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	675 K	595.8 K
Gross Profit Margin	0.89	0.79

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC